Острая декомпенсация сердечной недостаточности: состояние проблемы

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021:ehab368. DOI:10.1093/eurheartj/ehab368
2. Терещенко С.Н., Галявич А.С., Ускач Т.М., и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):311-74 [Tereshchenko SN, Galyavich AS, Uskach TM. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311-74 (in Russian)].  DOI:10.15829/1560-4071-2020-4083
3. Терещенко С.Н., Жиров И.В., Ускач Т.М., и др. Клинические рекомендации Евразийской ассоциации кардиологов (ЕАК)/Национальное общество специалистов по заболеваниям миокарда и сердечной недостаточности (НОИСН) по диагностике и лечению хронической сердечной недостаточности (2020). Евразийский кардиологический журнал. 2020;3:6-76 [Tereshchenko SN, Zhirov IV, Uskach TM, et al. Eurasian association of cardiology (EAC)/national society of heart failure and myocardial disease (NSHFMD) guidelines for the diagnosis and treatment of chronic heart failure (2020). Eur Heart J. 2020;3:6-76 (in Russian)].  DOI:10.38109/2225-1685-2020-3-6-76
4. Бойцов С.А., Терещенко С.Н., Жиров И.В., Агеев Ф.Т. Совершенствование оказания медицинской помощи больным с хронической сердечной недос- таточностью. Методические рекомендации. М.: ФГБУ «НМИЦ кардиологии» Минздрава России, 2020 [Boitsov SA, Tereshchenko SN, Zhirov IV, Ageev FT. Sovershenstvovanie okazaniia meditsinskoi pomoshchi bol'nym s khronicheskoi serdechnoi nedostatochnost'iu. Metodicheskie rekomendatsii. Moscow: FGBU “NMITs kardiologii” Minzdrava Rossii, 2020 (in Russian)].
5. Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-31. DOI:10.1002/ejhf.1494
6. Lichtenstein D, Axler O. Intensive use of general ultrasound in the intensive care unit (a prospective study of 150 consecutive patients). Intensive Care Med. 1993;19:353-5. DOI:10.1007/BF01694712
7. Picano E, Scali M, Ciampi Q, et al. Lung Ultrasound for the Cardiologist. JACC: Cardiovasc Imaging. 2018;11(11):1692-705. DOI:10.1016/j.jcmg.2018.06.023
8. Jambrik Z, Monti S, Coppola V, Agricola E, et al. Usefulness of ultrasound lung comets as a nonradiologic sign of extravascular lung water. Am J Cardiol. 2004;93:1265-70. DOI:10.1016/j.amjcard.2004.02.012
9. Volpicelli G, Elbarbary M, Blaivas M, et al. International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med. 2012;38:577.
DOI:10.1007/s00134-012-2513-4
10. Khosla R. Bedside Lung Ultrasound in Emergency (BLUE) Protocol: A Suggestion to Modify. Chest. 2010;137(6):1487-93. DOI:10.1378/chest.09-3123
11. Жиров И.В., Терещенко С.Н., Павленко Т.А. Использование ультразвукового исследования легких для оценки декомпенсации сердечной недостаточности и необходимости коррекции диуретической терапии. Неотложная кардиология. 2019;2:24-34 [Zhirov IV, Tereshchenko SN, Pavlenko TA. Usage of lung ultrasound for diagnostics of heart failure decompensation and control of diuretic therapy. Emergency Cardiology. 2019;2:24-34 (in Russian)]. DOI:10.25679/EMERGCARDIQLQGY.2019.23.97.003
12. Rappaport D. Noninvasive monitoring of pulmonary congestion using a remote dielectric sensing (ReDS) system: a prospective single-arm study in patients suffering from heart failure. J Card Fail. 2012;18(Suppl. 8):S61.
13. Bensimhon D. The use of the reds noninvasive lung fluid monitoring system to assess readiness for discharge in patients hospitalized with acute heart failure: A pilot study. Heart Lung. 2021;50(1):59-64. DOI:10.1016/j.hrtlng.2020.07.003
14. Abraham WT, Bensimhon D, Pinney SP, et al. Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial. ESC Heart Fail. 2021;8(5):3472-82. DOI:10.1002/ehf2.13550
15. Терещенко С.Н., Еременко А.А., Жиров И.В. Острая сердечная недостаточность. Интенсивная терапия. Национальное руководство. Под ред. И.Б. Заболотских, Д.Н. Проценко. Т. 1. М.: ГЭОТАР-Медиа, 2020; c.1063-85 [Tereshchenko SN, Eremenko AA, Zhirov IV. Ostraia serdechnaia nedostatochnost'. Intensivnaia terapiia. Natsional'noe rukovodstvo. Pod red. IB Zabolotskikh, DN Protsenko. T. 1. Moscow: GEOTAR-Media, 2020; p.1063-85 (in Russian)].
16. Velazquez E, Morrow D, DeVore A, et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380:539-48.  DOI:10.1056/NEJMoa1812851
17. McMurray JV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995-2008. DOI:10.1056/NEJMoa1911303
18. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-24. DOI:10.1056/NEJMoa2022190
19. Арутюнов Г.П., Лопатин Ю.М., Аметов А.С., и др. Эмпаглифлозин и сердечная недостаточность: согласованное мнение экспертов по результатам онлайн-совещания и обсуждения исследования EMPEROR-Preserved. Терапевтический архив. 2021;93(12):1491-7 [Arutyunov GP, Lopatin YuM, Ametov AS, et al. Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(12):1491-7  (in Russian)]. DOI:10.26442/00403660.2021.12.201281
20. Tromp J, Ponikowski P, Salsali A, et al. Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. Eur J Heart Fail.  2021;23:826-34. DOI:10.1002/ejhf.2137
21. Лаптева А.Е., Насонова С.Н., Жиров И.В., Терещенко С.Н. Ингибиторы SGLT2 и острая декомпенсация сердечной недостаточности, что мы знаем? Терапевтический архив. 2022;94(4):565-71 [Lapteva AE, Nasonova SN, Zhirov IV, Tereshchenko SN. SGLT2 inhibitors in acute decompensated heart failure, what do we know? Terapevticheskii Arkhiv (Ter. Arkh.).  2022;94(4):565-71 (in Russian)]. DOI:10.26442/00403660.2022.04.201449

________________________________________________

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021:ehab368. DOI:10.1093/eurheartj/ehab368
2. Tereshchenko SN, Galyavich AS, Uskach TM. 2020 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2020;25(11):311-74 (in Russian).  DOI:10.15829/1560-4071-2020-4083
3. ereshchenko SN, Zhirov IV, Uskach TM, et al. Eurasian association of cardiology (EAC)/national society of heart failure and myocardial disease (NSHFMD) guidelines for the diagnosis and treatment of chronic heart failure (2020). Eur Heart J. 2020;3:6-76 (in Russian).  DOI:10.38109/2225-1685-2020-3-6-76
4. Boitsov SA, Tereshchenko SN, Zhirov IV, Ageev FT. Sovershenstvovanie okazaniia meditsinskoi pomoshchi bol'nym s khronicheskoi serdechnoi nedostatochnost'iu. Metodicheskie rekomendatsii. Moscow: FGBU “NMITs kardiologii” Minzdrava Rossii, 2020 (in Russian).
5. Mueller C, McDonald K, de Boer RA, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail. 2019;21(6):715-31. DOI:10.1002/ejhf.1494
6. Lichtenstein D, Axler O. Intensive use of general ultrasound in the intensive care unit (a prospective study of 150 consecutive patients). Intensive Care Med. 1993;19:353-5. DOI:10.1007/BF01694712
7. Picano E, Scali M, Ciampi Q, et al. Lung Ultrasound for the Cardiologist. JACC: Cardiovasc Imaging. 2018;11(11):1692-705. DOI:10.1016/j.jcmg.2018.06.023
8. Jambrik Z, Monti S, Coppola V, Agricola E, et al. Usefulness of ultrasound lung comets as a nonradiologic sign of extravascular lung water. Am J Cardiol. 2004;93:1265-70. DOI:10.1016/j.amjcard.2004.02.012
9. Volpicelli G, Elbarbary M, Blaivas M, et al. International evidence-based recommendations for point-of-care lung ultrasound. Intensive Care Med. 2012;38:577.
DOI:10.1007/s00134-012-2513-4
10. Khosla R. Bedside Lung Ultrasound in Emergency (BLUE) Protocol: A Suggestion to Modify. Chest. 2010;137(6):1487-93. DOI:10.1378/chest.09-3123
11. Zhirov IV, Tereshchenko SN, Pavlenko TA. Usage of lung ultrasound for diagnostics of heart failure decompensation and control of diuretic therapy. Emergency Cardiology. 2019;2:24-34 (in Russian). DOI:10.25679/EMERGCARDIQLQGY.2019.23.97.003
12. Rappaport D. Noninvasive monitoring of pulmonary congestion using a remote dielectric sensing (ReDS) system: a prospective single-arm study in patients suffering from heart failure. J Card Fail. 2012;18(Suppl. 8):S61.
13. Bensimhon D. The use of the reds noninvasive lung fluid monitoring system to assess readiness for discharge in patients hospitalized with acute heart failure: A pilot study. Heart Lung. 2021;50(1):59-64. DOI:10.1016/j.hrtlng.2020.07.003
14. Abraham WT, Bensimhon D, Pinney SP, et al. Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial. ESC Heart Fail. 2021;8(5):3472-82. DOI:10.1002/ehf2.13550
15. Tereshchenko SN, Eremenko AA, Zhirov IV. Ostraia serdechnaia nedostatochnost'. Intensivnaia terapiia. Natsional'noe rukovodstvo. Pod red. IB Zabolotskikh, DN Protsenko. T. 1. Moscow: GEOTAR-Media, 2020; p.1063-85 (in Russian).
16. Velazquez E, Morrow D, DeVore A, et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N Engl J Med. 2019;380:539-48.  DOI:10.1056/NEJMoa1812851
17. McMurray JV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995-2008. DOI:10.1056/NEJMoa1911303
18. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-24. DOI:10.1056/NEJMoa2022190
19. Arutyunov GP, Lopatin YuM, Ametov AS, et al. Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial. Terapevticheskii Arkhiv (Ter. Arkh.). 2021;93(12):1491-7  (in Russian). DOI:10.26442/00403660.2021.12.201281
20. Tromp J, Ponikowski P, Salsali A, et al. Sodium-glucose co-transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial. Eur J Heart Fail.  2021;23:826-34. DOI:10.1002/ejhf.2137
21. Lapteva AE, Nasonova SN, Zhirov IV, Tereshchenko SN. SGLT2 inhibitors in acute decompensated heart failure, what do we know? Terapevticheskii Arkhiv (Ter. Arkh.).  2022;94(4):565-71 (in Russian). DOI:10.26442/00403660.2022.04.201449

И.В. Жиров1,2, С.Н. Насонова*1, С.Н. Терещенко1,2

1 ФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава России, Москва, Россия;
2 ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия
*dr.nasonova@mail.ru

________________________________________________

Igor V. Zhirov1,2, Svetlana N. Nasonova*1, Sergey N. Tereshchenko1,2

1 Chazov National Medical Research Center of Cardiology, Moscow, Russia;
2 Russian Medical Academy of Continuous Professional Education, Moscow, Russia
*dr.nasonova@mail.ru